Inhibition of ASM is already a promising therapeutic approach for MDD, and it targets the metabolism of sphingolipids, so several antidepressants seem to inhibit the upregulation of this enzyme in patients with MDD [74]. This evidence concerns the gene SMPD1 and major depressive disorder.